PERSANTINE
LOE ApproachingNDAORALTABLET
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERSANTINE is an oral small-molecule tablet approved in 1961 by Boehringer Ingelheim. The drug's specific mechanism of action and indications are not specified in available data, but it represents a legacy product with over 60 years of clinical use. As an NDA-approved small molecule, it likely addresses a chronic or cardiovascular condition.
LOE Approaching
With lifecycle status approaching loss of exclusivity and moderate competitive pressure (30% rating), the brand team likely operates in defensive/maintenance mode with focus on generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
Started Sep 2005
221 enrolled
IschemiaCoronary Disease
Persantine: Variation in Response Trial
Started Sep 2002
8 enrolled
Coronary Artery Disease
Career Relevance
Working on PERSANTINE offers limited growth career trajectory given the LOE-approaching lifecycle stage and lack of active clinical pipeline. Professionals should expect focus on market defense, generic transition planning, and operational efficiency rather than innovation or expansion.
Brand Manager
Worked on PERSANTINE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.